SpringTide Ventures

We strive to invest in companies that develop innovative drugs, medical devices and diagnostics. We focus on generating strong financial returns from our portfolio of venture companies. We invest in both private and public companies from an open evergreen fund. This funding structure enables us to take a long-term perspective. With colleagues on the ground in Copenhagen, London, Singapore, San Francisco and Boston, we are well positioned in the major global life science hubs and can quickly respond to new and exciting investment opportunities wherever they emerge. We primarily invest in biotechnology and medical technology. Within biotech we primarily invest in companies with clinical stage compounds. In medtech, we invest in commercial stage companies. We work actively with the companies we invest in by serving on the Boards of Directors. Companies can also draw on our extensive network, as well as our commercial and scientific expertise within the life sciences. During 2021, Novo Ventures executed 46 investments. We deployed DKK 3.2 billion during the year. Investment highlights include: Verve Therapeutics, a gene editing company hoping to lower LDL cholesterol for familial hypercholesterolemia and one of the first in vivo gene editing therapies to begin clinical trials Hummingbird Biosciences, a company using a systems biology approach to antibody discovery and development, and our first venture portfolio company with headquarters in Asia Numab Therapeutics, a next generation antibody fragment platform company whose lead programme has the potential to become new standard of care in immune checkpoint therapy Noom, a leading, high growth, global digital health platform

Canada’s leading digital healthcare Venture Capital firm, offering local depth with global reach. We are healthcare practitioners, operators and founders with over 100 years’ experience and a deep network. We focus on early stage and high-growth companies shaping the future of healthcare delivery and empowering them to scale and grow. How We InvestStage: Investments will be in early stage companies ranging from pre-Seed rounds through pre-IPO with initial investments focused on Seed and Series A rounds Areas: We look for groundbreaking HealthTech ideas focusing on digitization of healthcare, emergence of consumer MedTech, and consumerization of health and wellness Locations: We invest primarily in companies located in Canada, the US and Israel that target markets in North America and Europe

We are Lumira Ventures. $450M+ Invested: Over more than two decades, our firm has invested over $1B via multiple investment funds. $70B+ Cumulative Revenue of Portfolio Company Products: The 40+ products brought from discovery to market by our portfolio companies have generated over $60B of cumulative revenue. 100+ Companies Funded: We leverage the lessons learned from helping create, finance and build over 100 innovative healthcare companies. 27+ Average Years Partner Experience: Our portfolio companies take advantage of one of the most experienced and stable team of venture capital partners in North America. 1B+ Patients Worldwide: The areas of medical need being tackled by our companies include diabetes, Alzheimer’s, vision loss, heart failure, asthma, infectious disease and others that impact the daily lives of over 1 billion people worldwide. Focus Geography: Canada and U.S. Stage: Mix of early, clinical and revenue stage companies that are both privately held and publically traded Sectors: Biotechnology, medical technologies, digital health and consumer healthcare solutions Strategy Lumira executes a consistent, proven investment strategy as a lead investor and active partner with our portfolio companies. We focus on companies whose products offer transformative (not incremental) improvements to patient health outcomes, and the promise of dramatic reductions in the cost of healthcare delivery. Our Canadian heritage helps us “skate to where the puck is going to be,” investing in the new science and clinical insights that we expect will be driving the next decade of patient care. Differentiation Since our inception, we’ve been a different type of venture capital investor. We often focus on backing companies in regions of North America bypassed by most other investors. We manage right-sized funds where the financial interests of our fund investors are tightly aligned with our own. And we differentiate ourselves to entrepreneurs as an investor-of-choice by helping them leverage our multi-decade team stability, global industry relationships and lessons learned from building over 100 companies over our careers.

Our portfolio includes companies at all stages of development, from early-stage companies testing transformative technologies to commercial-stage companies seeking additional growth. With a focus on areas with significant unmet need, Vertex seeks to build great companies that improve the health and quality of human life. We take an active role in our portfolio companies and work with exceptional entrepreneurs, industry partners and fellow venture investors to create value. Our global investment professionals bring deep scientific, medical and business knowledge to every investment we make. In an increasingly globalized economy, Vertex Ventures HC offers global expertise to companies around the world. With offices in Silicon Valley and Singapore, our investment team scouts and invests in promising companies in the U.S., Asia and beyond. Our team, along with our network of scientific advisors and venture partners, has deep local networks and capabilities in both emerging and established markets. Our agile structure means we can act quickly on investment opportunities.

Intuitive Ventures invests in and accelerates the digital, therapeutic, diagnostic, and device ecosystems of minimally invasive care. Our unique access to Intuitive’s industry-leading knowledge, care delivery innovation, and commercial reach, empowers us to cultivate the potential of startups that are advancing positive outcomes in healthcare. Through our inaugural $100 million fund, Intuitive Ventures is focused on accelerating the future of minimally invasive care by moving the ecosystem forward. What we do Intuitive Ventures extends Intuitive's commitment to converging robotic systems, digital tools, and clinical need in search of new ways to understand, diagnose, treat, and manage disease. We apply Intuitive’s strengths and abilities in the fields of robotic surgery and minimally invasive care to support independent initiatives in four focus areas: Digital – transformative business models and solutions improving outcomes across the patient care continuum Therapeutics – precision focal therapeutics and biotech innovations delivered to the right patient at the right place and the right time Diagnostics – powering earlier disease detection and therapeutic activation across clinical pathways Devices – novel and digitally-native medical device platforms pushing the boundaries of patient care What sets us apart: Aligned for success – our nimble structure and financial alignment empower us to invest early and to support our portfolio companies pioneer markets Wealth of experience – we provide the resources and guidance needed to support our entrepreneurs and management teams reach their major milestones Deep strategic value – we leverage the unique strengths of Intuitive to accelerate the impact of our portfolio companies

Dreamit Healthtech focuses on digital health, medical device, and diagnostics startups. Dreamit company founders have myriad opportunities to meet, pilot, and partner with leading health systems, payers, pharmaceutical companies, medical device manufacturers, and self-insured employers. Dreamit Securetech focuses on cybersecurity, anti-fraud, risk & compliance, and physical security startups. Dreamit company founders have myriad opportunities to meet, pilot, and partner with leaders at Fortune 1,000 companies, hospital systems, federal agencies, and the military.